Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

• Publication date

  2013-05-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/EdBook_AM.2013.33.393PMID 23714558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases

  2013cited by this paper
• BRAF inhibitor activity in V600R metastatic melanoma.

  2013cited by this paper
• Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib.

  2013cited by this paper
• Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.

  2012cited by this paper
• Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

  2012cited by this paper
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM)

  2012cited by this paper
• Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab

  2012cited by this paper
• Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436).

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

  2012cited by this paper
• Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

  2012cited by this paper
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

  2012cited by this paper
• Evolution of end points for cancer immunotherapy trials.

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• Frequency of mutations associated with targeted therapy in malignant melanoma patients.

  2011cited by this paper
• Prognostic factors for survival in melanoma patients with brain metastases

  2011cited by this paper
• A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Vemurafenib for melanoma metastases to the brain.

  2011cited by this paper
• Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

  2011cited by this paper
• Determinants of survival in patients with brain metastases from cutaneous melanoma

  2010cited by this paper
• Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma

  2008cited by this paper
• CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

  2008cited by this paper
• The Catalogue of Somatic Mutations in Cancer (COSMIC)

  2008cited by this paper
• Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma

  2007cited by this paper
• Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

  2004cited by this paper
• Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.

  2004cited by this paper
• Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

  2004cited by this paper
• Determinants of outcome in melanoma patients with cerebral metastases.

  2004cited by this paper
• A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

  2003cited by this paper
• A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

  2003cited by this paper
• Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

  2002cited by this paper
• Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases

  2002cited by this paper
• Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

  1990cited by this paper
• Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex.

  1989cited by this paper
• Patterned distribution of metastases from malignant melanoma in humans.

  1983cited by this paper
• The current causes of death in patients with malignant melanoma.

  1978cited by this paper
• Metastatic pattern of malignant melanoma. A study of 216 autopsy cases.

  1978cited by this paper

• Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.

  2026cites this paper
• The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis

  2025cites this paper
• Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project

  2025cites this paper
• Treatment of Melanoma Metastasis: Surgical, Chemotherapy, and Innovation

  2023influential citation
• Real-world data on melanoma brain metastases and survival outcome

  2022cites this paper
• Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention

  2022cites this paper
• A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday.

  2021cites this paper
• Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain

  2020cites this paper
• Metastatic melanoma: Surgical treatment of brain metastases - Analysis of 110 patients.

  2020cites this paper
• Outcomes of Treatment for Melanoma Brain Metastases

  2020cites this paper
• PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma.

  2020cites this paper
• Current State of Target Treatment in BRAF Mutated Melanoma

  2020cites this paper
• Brain Metastases: Introduction

  2020cites this paper
• Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis.

  2020cites this paper
• Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer

  2019influential citation
• Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.

  2019cites this paper
• Targeting Molecular Pathways in Intracranial Metastatic Disease

  2019cites this paper
• Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers

  2019cites this paper
• Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

  2019cites this paper
• Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

  2019cites this paper
• Purely Meningeal Intracranial Relapse of Melanoma Brain Metastases after Surgical Resection and Immunotherapy as a Unique Disease Progression pattern: Our Experience and Review of the Literature.

  2019cites this paper
• Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking

  2018cites this paper
• SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases

  2018cites this paper
• Management of intracranial melanomas in the era of precision medicine

  2017cites this paper
• Management of intracranial melanomas in the era of precision medicine.

  2017cites this paper
• Primary intracranial melanoma

  2017cites this paper
• Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

  2017cites this paper
• Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

  2017cites this paper
• Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy.

  2017cites this paper
• Stereotactic Radiosurgery for Melanoma Brain Metastases: A Comprehensive Clinical Case Series.

  2017cites this paper
• Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.

  2016cites this paper
• Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?

  2016cites this paper
• KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy

  2016cites this paper
• Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

  2016cites this paper
• Targeted Therapy in Brain Metastases: Ready for Primetime?

  2016cites this paper
• Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.

  2015cites this paper
• Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications

  2015cites this paper
• Clinical Utility of BRAF-Targeted Therapy in Melanoma

  2015cites this paper
• Hepatoblastoma in Switzerland

  2015cites this paper
• Prognostic scores for brain metastasis patients: use in clinical practice and trial design.

  2015cites this paper
• Systemic therapies for melanoma brain metastases: which drug for whom and when?

  2015cites this paper
• Patients' Outcomes following Stereotactic Radiosurgery for Melanoma Brain Metastases

  2014cites this paper
• Melanoma m1: diagnosis and therapy.

  2014cites this paper
• Whole-brain radiotherapy in patients with brain metastases from melanoma.

  2014cites this paper
• Microsurgery for the treatment of primary malignant intracranial melanoma: a surgical series and literature review.

  2014cites this paper
• Checkpoint inhibitors in the treatment of cutaneous malignant melanoma.

  2014cites this paper
• Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib

  2014cites this paper
• Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases.

  2013cites this paper